Vall d'Hebron Talks by VHIR 'Targeting of monocytes and tumor-associated macrophages in cancer: lessons and perspectives'

 Vall d'Hebron Talks by VHIR
  Boardroom of the VHIR Edifici Central (Floor 0) — See in map
15/10/2025
15/10/2025 -- From 12:00h to 13:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: In-person
Share it:

Speaker: Dr. Julia Kzhyshkowska, Head of Dept. of Innate Immunity and Tolerance. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University.

ÀBSTRACT
Cancer is one of the leading causes of death, reduced quality of life and disability worldwide. cancer-specific and patient-specific programming of innate immunity is needed for in the success in development of new anticancer therapies, for improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider. Intratumoral TAMs and their precursors, resident macrophages and circulating monocytes, are principal regulators of tumor progression and therapy resistance. The lecture will elucidate the progress in the identification of in subpopulations of circulating monocytes and intratumoral TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance. The state-of-the-art will be presented  in our knowledge on the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Novel mechanisms involved in the crosstalk between epigenetic, signalling, transcriptional and metabolic pathways in monocytes and TAMs will be addressed. The lecture will next focus on the molecular mechanisms that TAMs use to interfere with anticancer therapeutics, and will summarize and critically evaluate the most advanced data from the clinical trials, which are divided into 4 categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic engineering of anti-tumor macrophages.

Host: Dr. Matilde LLeonart, Research group leader "Head and neck cancer: Biomedical Research in Tumor Stem Cells" Vall Hebron Institut de Recerca (VHIR)

Online: https://gencat.zoom.us/j/83458935904

 

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.